On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Jul. 22, 2022, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the…
On Jul. 19, 2022, Novavax announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee…
On Jul. 19, 2022, Gilead Sciences and the European Commission announced a new joint procurement agreement (JPA) that…
On Jul. 19, 2022, the NIH announced that although COVID-19 booster vaccinations in adults elicit high levels of…
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Jul. 13, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…
On Jul. 5, 2022, the National Institutes of Health released a study that described the immune response triggered…
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
On Jun. 30, 2022, Pfizer and BioNTech announced a vaccine supply agreement with the U.S. government to support…
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…